NCCN Announces Collaboration with Myovant Sciences and Pfizer to Support Projects to Understand and Mitigate Cardiovascular Risk in Patients with Prostate Cancer

/PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced a collaboration with Pfizer and Myovant...

Related Keywords

Balaji Tamarappoo ,Daniel Geynisman ,Facebook Nccnorg ,Instagram Nccnorg ,Zhaoping Li ,Camille Ragin ,Vivek Narayan ,Alicia Morgans ,David Geffen School Of Medicine ,Myovant Sciences ,Bren Simon Comprehensive Cancer Center ,Abramson Cancer Center ,Oncology Research Program ,National Comprehensive Cancer Network Oncology Research Program ,Pfizer ,Indiana University Melvin ,Scientific Review Committee ,University Of Pennsylvania ,Dana Farber Cancer Institute ,National Comprehensive Cancer Network ,Fox Chase Cancer Center ,Senior Vice President ,Chief Scientific Officer ,David Geffen School ,Nutritional Approach ,Lower Cardiovascular Risk Factors ,Men Undergoing Androgen Deprivation ,Dana Farber Cancer ,Cardiovascular Care ,Androgen Related Effects ,Prostate Cancer ,Abramson Cancer ,Cardiovascular Risk Evaluation ,Pilot Feasibility Study ,Assess Patient Awareness ,Fox Chase Cancer ,African Genetic Ancestry ,Cardiovascular Complications ,Prostate Cancer Patients Post Treatment ,Androgen Deprivation ,Bren Simon Comprehensive Cancer ,Medical Treatment ,Coronary Atherosclerosis ,Prostate Cancer Patients Guided ,Plaque Assessment ,Quantitative Coronary ,National Comprehensive Cancer ,Practice Guidelines ,